Treatment IND in Saudi Arabia
How the treatment ind pathway operates in Saudi Arabia.
About Treatment IND
US FDA treatment Investigational New Drug category.
How Treatment IND works in Saudi Arabia
The Saudi Food and Drug Authority (SFDA) operates a Personal Import / Unregistered Medicine pathway for named patients, typically requiring physician justification and hospital ethics-committee review.
Patients in Saudi Arabia seeking access under Treatment IND typically follow this flow: a licensed physician in Saudi Arabia issues the prescription and clinical justification, the regulator reviews and authorises, and an authorised operator coordinates import.
Documents required in Saudi Arabia
- Physician prescription and clinical-justification letter.
- Patient identification and consent.
- Country-specific NPP/personal-import form.
- Hospital or clinic attestation where required.
Typical timeline
End-to-end 2-6 weeks in most tier 1 jurisdictions. Cellular and gene therapies may require additional ethics-committee review.